ZYUS Life Sciences Increases Global Patient Access to Medical Cannabinoids in Australia with Health House International Sales and Distribution Agreement
New agreement will enable patients in Australia to access ZYUS’ cannabinoid formulations as part of international expansion
SASKATOON, Saskatchewan (BUSINESS WIRE) ZYUS Life Sciences Inc. ( ZYUS ), a Canadian life sciences company leading scientific research and development in phyto-therapeutics, is pleased to announce that it has entered a new non-exclusive, multiyear agreement with Australian medical cannabis importer, HHI (Australia) Pty Ltd
(“Health House”), to sell and distribute ZYUS’ cannabinoid formulations to medical patients through wholesale agents, such as pharmacies and hospitals. The agreement covers cannabinoid formulations including oils, as well as future product categories when they become available, with supply expected to hit the Australian market as early as the second half of 2021.